Sigma-Aldrich's fine chemicals business, SAFC, had its best quarter of 2009 in Q4, meeting the company's expectations of improved sales as the year ended. CFO, Rakesh Sachdev, put this down to "continued demand for adjuvant products for the H1N1 vaccine production and industrial media for pharmaceutical customers, as well as customer efforts to push early stage clinical trials".
Seeking Alpha
Saturday, 13 February 2010
Year ends with an upturn for SAFC
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment